

Via EFS

Date of Deposit: September 10, 2010

Attorney Docket No.: 16534-539001US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Levy, et al.	CONFIRMATION No.	8952
SERIAL No.:	10/692,764	EXAMINER:	Janet L. Epps Smith
FILING DATE:	October 24, 2003	ART UNIT:	1633
FOR:	METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

This Information Disclosure Statement is accompanied by the statement that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of this statement. This Information Disclosure Statement contains art cited by the European Patent Office in the Supplementary Search Report for Application Number EP 03781397.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


APPLICANT: Levy, et al.
U.S.S.N.: 10/692,764

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.: 16534-539001US.

Respectfully submitted,



Heidi A. Erlacher, Reg. No. 45,409
Christopher E. Olson, Reg. No. 55,510
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Date: September 10, 2010

5017765v.1